mrna-4157
Vaccineexperimental
Clinical trial activity
11 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
9
Phase 3
4
Phase 4
0
Earliest trial started Aug 14, 2017 (NCT03313778)
Timeline
Indications
Mechanism of action
- Tumor antigensImmunity, active
immunity, active - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07221474 | Phase 2 | Dec 2, 2025 | Merck, Moderna Therapeutics |
| NCT06961006 | Phase 2 | May 29, 2025 | Merck |
| NCT06833073 | Phase 2 | Mar 17, 2025 | Merck, Moderna Therapeutics |
| NCT06623422 | Phase 3 | Oct 21, 2024 | Merck, Moderna Therapeutics |
| NCT06295809 | Phase 2/Phase 3 (Phase 3) | Apr 18, 2024 | Merck, Moderna Therapeutics |
| NCT06307431 | Phase 2 | Apr 10, 2024 | Merck, Moderna Therapeutics |
| NCT06305767 | Phase 1/Phase 2 (Phase 2) | Mar 28, 2024 | Merck, Moderna Therapeutics |
| NCT06077760 | Phase 3 | Dec 6, 2023 | Merck, Moderna Therapeutics |
| NCT05933577 | Phase 3 | Jul 19, 2023 | Merck, Moderna Therapeutics |
| NCT03897881 | Phase 2 | Jul 31, 2019 | Merck, Moderna Therapeutics |
| NCT03313778 | Phase 1 | Aug 14, 2017 | Merck, Moderna Therapeutics |
Showing 11 of 11 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck | For profit | 11 | 9 | 3 | 2017 |
| Moderna Therapeutics | For profit | 10 | 2 | 3 | 2017 |
2 organizations
Page 1 / 1